Related references
Note: Only part of the references are listed.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Thromboembolism and Janus Kinase Inhibitors
Fowzia Ibrahim et al.
DRUG SAFETY (2020)
Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase
Enriqueta Vallejo-Yaguee et al.
DRUG SAFETY (2020)
Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
Suraj Rajasimhan et al.
DRUGS & AGING (2020)
DOES THE RISK OF VENOUS THROMBOEMBOLISM VARY WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS?
V. Molander et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
Wenhui Xie et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners
Rishi J. Desai et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study
Rishi J. Desai et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
Huifang Liang et al.
RMD OPEN (2019)
Cautionary Notes About Outpatient Treatment of Acute Pulmonary Embolism
Samuel Z. Goldhaber
CHEST (2018)
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Abril Verden et al.
DRUG SAFETY (2018)
A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent
Rishi J. Desai et al.
EPIDEMIOLOGY (2017)
A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data
Leonardo Tamariz et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
A combined comorbidity score predicted mortality in elderly patients better than existing scores
Joshua J. Gagne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Validation of rheumatoid arthritis diagnoses in health care utilization data
Seo Young Kim et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
Peter C. Austin
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION (2009)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Share Paper
